DrugPatentWatch Database Preview
Clovis Oncology Inc Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for CLOVIS ONCOLOGY INC, and what generic alternatives to CLOVIS ONCOLOGY INC drugs are available?
CLOVIS ONCOLOGY INC has one approved drug.
There are twelve US patents protecting CLOVIS ONCOLOGY INC drugs.
There are two hundred and forty-one patent family members on CLOVIS ONCOLOGY INC drugs in fifty-three countries and twenty-eight supplementary protection certificates in eighteen countries.
Summary for Clovis Oncology Inc
| International Patents: | 241 |
| US Patents: | 12 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Clovis Oncology Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | 10,130,636 | Start Trial | Start Trial | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | 8,143,241 | Start Trial | Start Trial | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | 10,278,974 | Start Trial | Y | Start Trial | |||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | 9,045,487 | Start Trial | Y | Y | Start Trial | ||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | 8,071,579 | Start Trial | Start Trial | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | 8,859,562 | Start Trial | Start Trial | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | 8,071,579 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Clovis Oncology Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2517629 | Start Trial |
| Hong Kong | 1094006 | Start Trial |
| Japan | 4027406 | Start Trial |
| Spain | 2545613 | Start Trial |
| Spain | 2753748 | Start Trial |
| South Korea | 102108226 | Start Trial |
| Estonia | 200100364 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Clovis Oncology Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2534153 | 300958 | Netherlands | Start Trial | PRODUCT NAME: RUCAPARIB CAMSYLAAT; REGISTRATION NO/DATE: EU/1/17/1250 20180529 |
| 1633724 | 2015/016 | Ireland | Start Trial | PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216 |
| 2534153 | 2018C/044 | Belgium | Start Trial | PRODUCT NAME: RUCAPARIB-CAMSYLAAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1250 20180529 |
| 1633724 | 92680 | Luxembourg | Start Trial | PRODUCT NAME: OLAPARIB AINSI QUE DES SELS ET DES SOLVATES DE CELUI-CI. FIRST REGISTRATION: 20141218 |
| 1633724 | 1590019-4 | Sweden | Start Trial | PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218 |
| 1633724 | 213 50005-2015 | Slovakia | Start Trial | PRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: EU/1/14/959 20141218 |
| 2534153 | 48/2018 | Austria | Start Trial | PRODUCT NAME: RUCAPARIBCAMSYLAT; REGISTRATION NO/DATE: EU/1/17/1250 (MITTEILUNG) 20180529 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
